Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Shares Outstanding (Weighted Average) (2020 - 2025)

Insight Molecular Diagnostics' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $32.0 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 133.58% year-over-year to $32.0 million; the TTM value through Sep 2025 reached $32.0 million, up 133.58%, while the annual FY2024 figure was $13.1 million, 70.84% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $32.0 million at Insight Molecular Diagnostics, up from $28.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $92.2 million in Q1 2022 and bottomed at $5135.0 in Q2 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $12.9 million (2024), against an average of $27.6 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) crashed 99.99% in 2022 before it surged 137584.91% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $88920.0 in 2021, then soared by 6130.32% to $5.5 million in 2022, then soared by 38.1% to $7.7 million in 2023, then skyrocketed by 70.84% to $13.1 million in 2024, then surged by 145.07% to $32.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Shares Outstanding (Weighted Average) are $32.0 million (Q3 2025), $28.9 million (Q2 2025), and $25.7 million (Q1 2025).